{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:52:35Z","timestamp":1784890355577,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Proyectos Integrados IBSAL","award":["IBY15\/00003"],"award-info":[{"award-number":["IBY15\/00003"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RICET VI PN I+D+I 2008-2011, ISCIII FEDER (RD12\/0018\/0002)"],"award-info":[{"award-number":["RICET VI PN I+D+I 2008-2011, ISCIII FEDER (RD12\/0018\/0002)"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010784","name":"Banco de Santander","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010784","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13071-016-1500-y","type":"journal-article","created":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T13:54:44Z","timestamp":1460987684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems"],"prefix":"10.1186","volume":"9","author":[{"given":"Bel\u00e9n","family":"Vicente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"L\u00f3pez-Ab\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Rojas-Caraballo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"del Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Fern\u00e1ndez-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,18]]},"reference":[{"key":"1500_CR1","unstructured":"WHO Schistosomiasis: number of people treated worldwide in 2013. Wkly Epidemiol Rec. 2015;90:25\u201332."},{"key":"1500_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.molbiopara.2014.06.002","volume":"195","author":"D Cioli","year":"2014","unstructured":"Cioli D, Pica-Mattoccia L, Basso A, Guidi A. Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol. 2014;195:23\u20139.","journal-title":"Mol Biochem Parasitol."},{"key":"1500_CR3","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1017\/S0031182013000231","volume":"140","author":"RM Greenberg","year":"2013","unstructured":"Greenberg RM. New approaches for understanding mechanisms of drug resistance in schistosomes. Parasitology. 2013;140:1534\u201346.","journal-title":"Parasitology."},{"key":"1500_CR4","doi-asserted-by":"crossref","first-page":"e45867","DOI":"10.1371\/journal.pone.0045867","volume":"7","author":"L P\u00e9rez del Villar","year":"2012","unstructured":"P\u00e9rez del Villar L, Burguillo FJ, L\u00f3pez-Ab\u00e1n J, Muro A. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One. 2012;7:e45867.","journal-title":"PLoS One"},{"key":"1500_CR5","doi-asserted-by":"crossref","first-page":"15058","DOI":"10.3390\/molecules190915058","volume":"19","author":"YX Liu","year":"2014","unstructured":"Liu YX, Wu W, Liang YJ, Jie ZL, Wang H, Wang W, Huang YX. New uses for old drugs: the tale of artemisinin derivatives in the elimination of schistosomiasis japonica in China. Molecules. 2014;19:15058\u201374.","journal-title":"Molecules."},{"key":"1500_CR6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13071-015-0766-9","volume":"8","author":"JE Grimes","year":"2015","unstructured":"Grimes JE, Croll D, Harrison WE, Utzinger J, Freeman MC, Templeton MR. The roles of water, sanitation and hygiene in reducing schistosomiasis: a review. Parasit Vectors. 2015;8:156.","journal-title":"Parasit Vectors."},{"key":"1500_CR7","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3389\/fimmu.2015.00390","volume":"6","author":"R Ridi El","year":"2015","unstructured":"El Ridi R, Othman AA, McManus DP. Editorial: the schistosomiasis vaccine - it is time to stand up. Front Immunol. 2015;6:390.","journal-title":"Front Immunol."},{"key":"1500_CR8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fimmu.2015.00085","volume":"6","author":"M Fukushige","year":"2015","unstructured":"Fukushige M, Mitchell KM, Bourke CD, Woolhouse ME, Mutapi F. A Meta-analysis of experimental studies of attenuated Schistosoma mansoni vaccines in the mouse model. Front Immunol. 2015;6:85.","journal-title":"Front Immunol."},{"key":"1500_CR9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-3024.2011.01330.x","volume":"34","author":"HE McWilliam","year":"2012","unstructured":"McWilliam HE, Driguez P, Piedrafita D, McManus DP, Meeusen EN. Novel immunomic technologies for schistosome vaccine development. Parasite Immunol. 2012;34:276\u201384.","journal-title":"Parasite Immunol."},{"key":"1500_CR10","doi-asserted-by":"crossref","first-page":"541268","DOI":"10.1155\/2012\/541268","volume":"2012","author":"CT Fonseca","year":"2012","unstructured":"Fonseca CT, Braz Figueiredo Carvalho G, Carvalho Alves C, de Melo TT. Schistosoma tegument proteins in vaccine and diagnosis development: an update. J Parasitol Res. 2012;2012:541268.","journal-title":"J Parasitol Res."},{"key":"1500_CR11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fimmu.2015.00022","volume":"6","author":"BC Figueiredo","year":"2015","unstructured":"Figueiredo BC, Ricci ND, de Assis NR, de Morais SB, Fonseca CT, Oliveira SC. Kicking in the Guts: Schistosoma mansoni Digestive Tract Proteins are Potential Candidates for Vaccine Development. Front Immunol. 2015;6:22.","journal-title":"Front Immunol."},{"key":"1500_CR12","doi-asserted-by":"crossref","first-page":"e1704","DOI":"10.1371\/journal.pntd.0001704","volume":"6","author":"G Riveau","year":"2012","unstructured":"Riveau G, Deplanque D, Remou\u00e9 F, Schacht AM, Vodougnon H, Capron M, Thiry M, Martial J, Libersa C, Capron A. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis. 2012;6:e1704.","journal-title":"PLoS Negl Trop Dis."},{"key":"1500_CR13","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1021\/pr1000785","volume":"9","author":"G Chemale","year":"2010","unstructured":"Chemale G, Perally S, LaCourse EJ, Prescott MC, Jones LM, Ward D, Meaney M, Hoey E, Brennan GP, Fairweather I, Trudgett A, Brophy PM. Comparative proteomic analysis of triclabendazole response in the liver fluke Fasciola hepatica. J Proteome Res. 2010;9:4940\u201351.","journal-title":"J Proteome Res."},{"key":"1500_CR14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13059-015-0632-2","volume":"16","author":"K Cwiklinski","year":"2015","unstructured":"Cwiklinski K, Dalton JP, Dufresne PJ, La Course J, Williams DJ, Hodgkinson J, Paterson S. The Fasciola hepatica genome: gene duplication and polymorphism reveals adaptation to the host environment and the capacity for rapid evolution. Genome Biol. 2015;16:71.","journal-title":"Genome Biol."},{"issue":"9","key":"1500_CR15","doi-asserted-by":"crossref","first-page":"e45974","DOI":"10.1371\/journal.pone.0045974","volume":"7","author":"A Marcilla","year":"2012","unstructured":"Marcilla A, Trelis M, Cort\u00e9s A, Sotillo J, Cantalapiedra F, Minguez MT, Valero ML, S\u00e1nchez del Pino MM, Mu\u00f1oz-Antoli C, Toledo R, Bernal D. Extracellular vesicles from parasitic helminths contain specific excretory\/secretory proteins and are internalized in intestinal host cells. PLoS One. 2012;7(9):e45974.","journal-title":"PLoS One"},{"key":"1500_CR16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fimmu.2015.00218","volume":"6","author":"M Tendler","year":"2015","unstructured":"Tendler M, Almeida M, Simpson A. Development of the Brazilian anti-schistosomiasis vaccine based on the recombinant fatty acid binding protein Sm14 plus GLA-SE adjuvant. Front Immunol. 2015;6:218.","journal-title":"Front Immunol."},{"key":"1500_CR17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1590\/S0074-02761995000200021","volume":"90","author":"GV Hillyer","year":"1995","unstructured":"Hillyer GV. Comparison of purified 12\u00a0kDa and recombinant 15\u00a0kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Mem Inst Oswaldo Cruz. 1995;90:249\u201353.","journal-title":"Mem Inst Oswaldo Cruz."},{"key":"1500_CR18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1079\/JOH2005304","volume":"79","author":"GV Hillyer","year":"2005","unstructured":"Hillyer GV. Fasciola antigens as vaccines against fascioliasis and schistosomiasis. J Helminthol. 2005;79:241\u20137.","journal-title":"J Helminthol."},{"key":"1500_CR19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12879-015-0906-z","volume":"15","author":"SF Mossallam","year":"2015","unstructured":"Mossallam SF, Amer EI, Ewaisha RE, Khalil AM, Aboushleib HM, Bahey-El-Din M. Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model. BMC Infect Dis. 2015;15:147.","journal-title":"BMC Infect Dis."},{"key":"1500_CR20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-4017(99)00053-9","volume":"83","author":"JL Ab\u00e1n","year":"1999","unstructured":"Ab\u00e1n JL, Ramajo V, Arellano JL, Oleaga A, Hillyer GV, Muro A. A fatty acid binding protein from Fasciola hepatica induced protection in C57\/BL mice from challenge infection with Schistosoma bovis. Vet Parasitol. 1999;83:107\u201321.","journal-title":"Vet Parasitol."},{"key":"1500_CR21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-4017(00)00263-6","volume":"91","author":"JL Ab\u00e1n\u00e9","year":"2000","unstructured":"Ab\u00e1n\u00e9 JL, Oleaga A, Ramajo V, Casanueva P, Arellano JL, Hillyer GV, Muro A. Vaccination of mice against Schistosoma bovis with a recombinant fatty acid binding protein from Fasciola hepatica. Vet Parasitol. 2000;91:33\u201342.","journal-title":"Vet Parasitol."},{"key":"1500_CR22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.exppara.2014.08.007","volume":"145","author":"B Vicente","year":"2014","unstructured":"Vicente B, L\u00f3pez-Ab\u00e1n J, Rojas-Caraballo J, P\u00e9rez del Villar L, Hillyer GV, Mart\u00ednez-Fern\u00e1ndez AR, Muro A. A Fasciola hepatica-derived fatty acid binding protein induces protection against schistosomiasis caused by Schistosoma bovis using the adjuvant adaptation (ADAD) vaccination system. Exp Parasitol. 2014;145:145\u201351.","journal-title":"Exp Parasitol"},{"key":"1500_CR23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exppara.2015.04.022","volume":"154","author":"B Vicente","year":"2015","unstructured":"Vicente B, L\u00f3pez-Ab\u00e1n J, Rojas-Caraballo J, del Olmo E, Fern\u00e1ndez-Soto P, Ramajo-Mart\u00edn V, Muro A. The combination of the aliphatic diamine AA0029 in ADAD vaccination system with a recombinant fatty acid binding protein could be a good alternative for the animal schistosomiasis control. Exp Parasitol. 2015;154:134\u201342.","journal-title":"Exp Parasitol."},{"key":"1500_CR24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3347\/kjp.2012.50.1.37","volume":"50","author":"I Rabia Aly","year":"2012","unstructured":"Rabia Aly I, Diab M, El-Amir AM, Hendawy M, Kadry S. Fasciola gigantica fatty acid binding protein (FABP) as a prophylactic agent against Schistosoma mansoni infection in CD1 mice. Korean J Parasitol. 2012;50:37\u201343.","journal-title":"Korean J Parasitol."},{"key":"1500_CR25","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.biotechadv.2012.01.009","volume":"30","author":"S Sokolenko","year":"2012","unstructured":"Sokolenko S, George S, Wagner A, Tuladhar A, Andrich JM, Aucoin MG. Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and drawbacks. Biotechnol Adv. 2012;30:766\u201381.","journal-title":"Biotechnol Adv"},{"key":"1500_CR26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.sbi.2013.03.009","volume":"23","author":"D Barford","year":"2013","unstructured":"Barford D, Takagi Y, Schultz P, Berger I. Baculovirus expression: tackling the complexity challenge. Curr Opin Struct Biol. 2013;23:357\u201364.","journal-title":"Curr Opin Struct Biol."},{"key":"1500_CR27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.vetpar.2004.07.023","volume":"126","author":"AR Mart\u00ednez-Fern\u00e1ndez","year":"2004","unstructured":"Mart\u00ednez-Fern\u00e1ndez AR, Nogal-Ruiz JJ, L\u00f3pez-Ab\u00e1n J, Ramajo V, Oleaga A, Manga-Gonz\u00e1lez Y, Hillyer GV, Muro A. Vaccination of mice and sheep with Fh12 FABP from Fasciola hepatica using the new adjuvant\/immunomodulator system ADAD. Vet Parasitol. 2004;126:287\u201398.","journal-title":"Vet Parasitol."},{"key":"1500_CR28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1645\/GE-2891.1","volume":"98","author":"J L\u00f3pez-Ab\u00e1n","year":"2012","unstructured":"L\u00f3pez-Ab\u00e1n J, Esteban A, Vicente B, Rojas-Caraballo J, del Olmo E, Mart\u00ednez-Fern\u00e1ndez AR, Hillyer GV, Muro A. Adaptive immune stimulation is required to obtain high protection with fatty acid binding protein vaccine candidate against Fasciola hepatica in BALB\/C mice. J Parasitol. 2012;98:527\u201335.","journal-title":"J Parasitol."},{"key":"1500_CR29","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1016\/j.bmcl.2006.08.113","volume":"16","author":"E Olmo del","year":"2006","unstructured":"del Olmo E, Plaza A, Muro A, Mart\u00ednez-Fern\u00e1ndez AR, Nogal-Ruiz JJ, L\u00f3pez-P\u00e9rez JL, Feliciano AS. Synthesis and evaluation of some lipidic aminoalcohols and diamines as immunomodulators. Bioorg Med Chem Lett. 2006;16:6091\u20135.","journal-title":"Bioorg Med Chem Lett."},{"key":"1500_CR30","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1645\/GE-999R2.1","volume":"93","author":"N Uribe","year":"2007","unstructured":"Uribe N, Muro A, Vieira C, L\u00f3pez-Ab\u00e1n J, del Olmo E, Su\u00e1rez L, Mart\u00ednez-Fern\u00e1ndez AR, Siles-Lucas M. Genetic and immunological characterization of the 14-3-3 molecule from Schistosoma bovis. J Parasitol. 2007;93:964\u20139.","journal-title":"J Parasitol."},{"key":"1500_CR31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0976-500X.119726","volume":"4","author":"J Charan","year":"2013","unstructured":"Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4:303\u20136.","journal-title":"J Pharmacol Pharmacother."},{"key":"1500_CR32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ilar.43.4.244","volume":"43","author":"MF Festing","year":"2002","unstructured":"Festing MF, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 2002;43:244\u201358.","journal-title":"ILAR J."},{"key":"1500_CR33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/0014-4894(92)90202-L","volume":"74","author":"J Rodr\u00edguez-P\u00e9rez","year":"1992","unstructured":"Rodr\u00edguez-P\u00e9rez J, Rodr\u00edguez-Medina JR, Garc\u00eda-Blanco MA, Hillyer GV. Fasciola hepatica: molecular cloning, nucleotide sequence, and expression of a gene encoding a polypeptide homologous to a Schistosoma mansoni fatty acid-binding protein. Exp Parasitol. 1992;74:400\u20137.","journal-title":"Exp Parasitol."},{"key":"1500_CR34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25\u00a0years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods."},{"key":"1500_CR35","doi-asserted-by":"crossref","first-page":"e105323","DOI":"10.1371\/journal.pone.0105323","volume":"9","author":"J Rojas-Caraballo","year":"2014","unstructured":"Rojas-Caraballo J, L\u00f3pez-Ab\u00e1n J, P\u00e9rez del Villar L, Vizca\u00edno C, Vicente B, Fern\u00e1ndez-Soto P, del Olmo E, Patarroyo MA, Muro A. In vitro and in vivo studies for assessing the immune response and protection-inducing ability conferred by Fasciola hepatica-derived synthetic peptides containing B- and T-cell epitopes. PLoS One. 2014;9:e105323.","journal-title":"PLoS One."},{"key":"1500_CR36","doi-asserted-by":"crossref","first-page":"e0003537","DOI":"10.1371\/journal.pntd.0003537","volume":"9","author":"CC Alves","year":"2015","unstructured":"Alves CC, Araujo N, dos Santos VC, Couto FB, Assis NR, Morais SB, Oliveira SC, Fonseca CT. Sm29, but not Sm22.6 retains its ability to induce a protective immune response in mice previously exposed to a Schistosoma mansoni infection. PLoS Negl Trop Dis. 2015;9:e0003537.","journal-title":"PLoS Negl Trop Dis"},{"key":"1500_CR37","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1016\/j.vaccine.2007.07.021","volume":"25","author":"M Siles-Lucas","year":"2007","unstructured":"Siles-Lucas M, Uribe N, L\u00f3pez-Ab\u00e1n J, Vicente B, Orfao A, Nogal-Ruiz JJ, Feliciano AS, Muro A. The Schistosoma bovis Sb14-3-3zeta recombinant protein cross-protects against Schistosoma mansoni in BALB\/c mice. Vaccine. 2007;25:7217\u201323.","journal-title":"Vaccine."},{"key":"1500_CR38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/CMR.00046-07","volume":"21","author":"DP McManus","year":"2008","unstructured":"McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev. 2008;21:225\u201342.","journal-title":"Clin Microbiol Rev."},{"key":"1500_CR39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/pim.12091","volume":"36","author":"TT Melo","year":"2014","unstructured":"Melo TT, Sena IC, Araujo N, Fonseca CT. Antibodies are involved in the protective immunity induced in mice by Schistosoma mansoni schistosomula tegument (Smteg) immunization. Parasite Immunol. 2014;36:107\u201311.","journal-title":"Parasite Immunol"},{"key":"1500_CR40","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00436-015-4341-2","volume":"114","author":"EA El-Shabasy","year":"2015","unstructured":"El-Shabasy EA, Reda ES, Abdeen SH, Said AE, Ouhtit A. Transmission electron microscopic observations on ultrastructural alterations in Schistosoma mansoni adult worms recovered from C57BL\/6 mice treated with radiation-attenuated vaccine and\/or praziquantel in addition to passive immunization with normal and vaccinated rabbit sera against infection. Parasitol Res. 2015;114:1563\u201380.","journal-title":"Parasitol Res."},{"key":"1500_CR41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.vetpar.2008.01.023","volume":"153","author":"J L\u00f3pez-Ab\u00e1n","year":"2008","unstructured":"L\u00f3pez-Ab\u00e1n J, Nogal-Ruiz JJ, Vicente B, Morrondo P, Diez-Ba\u00f1os P, Hillyer GV, Mart\u00ednez-Fern\u00e1ndez AR, Feliciano AS, Muro A. The addition of a new immunomodulator with the adjuvant adaptation ADAD system using fatty acid binding proteins increases the protection against Fasciola hepatica. Vet Parasitol. 2008;153:176\u201381.","journal-title":"Vet Parasitol."},{"key":"1500_CR42","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.vetpar.2006.12.017","volume":"145","author":"J L\u00f3pez-Ab\u00e1n","year":"2007","unstructured":"L\u00f3pez-Ab\u00e1n J, Casanueva P, Nogal J, Arias M, Morrondo P, Diez-Ba\u00f1os P, Hillyer GV, Mart\u00ednez-Fern\u00e1ndez AR, Muro A. Progress in the development of Fasciola hepatica vaccine using recombinant fatty acid binding protein with the adjuvant adaptation system ADAD. Vet Parasitol. 2007;145:287\u201396.","journal-title":"Vet Parasitol."},{"key":"1500_CR43","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/vaccines2030654","volume":"2","author":"R Stephenson","year":"2014","unstructured":"Stephenson R, You H, McManus DP, Toth I. Schistosome vaccine adjuvants in preclinical and clinical research. Vaccines (Basel). 2014;2:654\u201385.","journal-title":"Vaccines (Basel)"},{"key":"1500_CR44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.humpath.2004.10.016","volume":"36","author":"SJ Rodig","year":"2005","unstructured":"Rodig SJ, Shahsafaei A, Li B, Dorfman DM. The CD45 isoform B220 identifies select subsets of human B cells and B-cell lymphoproliferative disorders. Hum Pathol. 2005;36:51\u20137.","journal-title":"Hum Pathol."},{"key":"1500_CR45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4161\/bioe.20679","volume":"3","author":"HY Lu","year":"2012","unstructured":"Lu HY, Chen YH, Liu HJ. Baculovirus as a vaccine vector. Bioengineered. 2012;3:271\u20134.","journal-title":"Bioengineered."}],"container-title":["Parasites & Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-016-1500-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T18:53:52Z","timestamp":1589655232000},"score":1,"resource":{"primary":{"URL":"http:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-016-1500-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,18]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1186\/s13071-016-1500-y","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,18]]},"article-number":"216"}}